← Back to patent-cliff list
ONO-1110
Tier C — Watch / tradeONO-1110
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CB
Indications (approved)：间质性膀胱炎, Fibromyalgia, Postherpetic neuralgia, Anxiety, Major depressive disorder, Pain
Regional status
US
-
EU
-
China
-
Japan
Phase II
2025-01-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ONO-1110?
Approved indications include: 间质性膀胱炎, Fibromyalgia, Postherpetic neuralgia, Anxiety, Major depressive disorder, Pain.
When does the ONO-1110 patent expire?
No public expiry year is available for ONO-1110 yet; this page updates once verified.
How do I get a quote for ONO-1110 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01